This past spring we wrote about “The Only Telehealth Stock for Telemedicine Investors,” an article with a misleading title. That’s because there soon may be two pure-play stocks to consider in this space. In that article, we noted that none of the other major players in telehealth are publicly traded, but “that could change now that the window of interest in telehealth has opened.” It did change, as we may soon have another telehealth stock to consider.
Is Telehealth a Temporary Thesis?
We’re always quite cautious about investing in temporary trends. Whenever new viruses emerge in faraway places, you’ll see certain stocks react accordingly. Anyone remember Ebola stocks?
We want nothing to do with a temporary investing thesis in much the same way we want nothing to do with speculating. That’s why we’ve largely steered clear of the whole coronavirus vaccine thesis. Similarly, we’re a bit concerned that telehealth is only heated at the moment because of “the rona.” Look no further than
Sign up to our newsletter to get more of our great research delivered straight to your inbox!
Nanalyze Weekly includes useful insights written by our team of underpaid MBAs, research on new disruptive technology stocks flying under the radar, and summaries of our recent research. Always 100% free.
Become a premium member and get access to hundreds of premium articles, reports and additional content.
Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.